NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Seelos
Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, today
announced the promotions of Michael
Golembiewski to Chief Financial Officer and Anthony Marciano to Chief Communications
Officer, each effective September 1,
2021.
"I congratulate Michael and Anthony on their promotions, which
are a testament to their abilities, hard work and dedication to
Seelos," said Raj Mehra Ph.D., Chairman and CEO of Seelos.
Mr. Golembiewski joined Seelos in January
2019 as Vice President, Finance. Previously, he was Vice
President of Finance at Agile Therapeutics, Inc., a pre-commercial
biotechnology company. He was also Vice President of Finance,
Principal Accounting Officer and Corporate Controller at Pernix
Therapeutics Holdings, Inc., a global commercial life sciences
company. He was also Executive Director, Corporate Controller at
NPS Pharmaceuticals, Inc., a global commercial life sciences
company that was sold to Shire plc in 2015 for $5.2 billion. Mr. Golembiewski began his career
in the biotechnology field with ImClone Systems Incorporated. He is
a Certified Public Accountant (not in public practice) and obtained
his Bachelor of Science degree in accounting from Rider University.
Mr. Marciano began his work with Seelos as a consultant in
August 2017 and was appointed Head of
Corporate Communications in January
2019. His role at Seelos will continue to be spearheading
investor and media relations, introductions to advocacy groups,
investment bank interactions and general corporate communications
strategies. Mr. Marciano began as a healthcare-dedicated
institutional equity salesman at Leerink, Swann and Company
(currently Leerink Partners, LLC) in 2000 and immediately prior to
Seelos served as a Senior Vice President at Jefferies. He has
extensive experience interacting with the hedge fund and mutual
fund communities and deep knowledge of the investment banking
process including the structuring and placement of equity and debt
transactions. Mr. Marciano holds a Bachelor of Science degree in
Finance and Marketing from Manhattan
College and a Master of Business Administration from the
O'Malley School of Business at Manhattan
College.
Also, during the month of August, several Seelos employees,
including certain members of senior management, purchased shares of
Seelos stock in the open market.
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and advancement of novel
therapeutics to address unmet medical needs for the benefit of
patients with central nervous system (CNS) disorders and other rare
diseases. The Company's robust portfolio includes several
late-stage clinical assets targeting indications including Acute
Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder
(MDD) or Post-Traumatic Stress Disorder (PTSD), Amyotrophic
lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease,
other psychiatric and movement disorders plus orphan diseases.
For more information, please visit our website:
http://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Forward Looking Statements
Statements made in this press release, which are not
historical in nature, constitute forward-looking statements for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations and beliefs and are subject to a
number of factors and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. All information in this press release is as of
September 1, 2021 and we undertake no
duty to update this information. A more complete description of
these risks can be found in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K for
the year-ended December 31, 2020 and
our Quarterly Report on Form 10-Q for the quarter-ended
June 30, 2021.
Contact Information:
Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original content to download
multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-senior-management-appointments-301366723.html
SOURCE Seelos Therapeutics, Inc.